About: Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium
Creator	Li, Xiangdong Shi, Yi Wang, Han Zhang, Jingyuan Du, Xiaohong Fan, Hanlu Gao, George Li, Haifeng Lu, Xiaohui Tan, Dun-Xian Wu, Qihui Zheng, Han Zhou, Zhuan
Source	PMC
abstract	The Ebola crisis occurred in West-Africa highlights the urgency for its clinical treatments. Currently, no Food and Drug Administration (FDA)-approved therapeutics are available. Several FDA-approved drugs, including selective estrogen receptor modulators (SERMs), possess selective anti-Ebola activities. However, the inhibitory mechanisms of these drugs remain elusive. By analyzing the structures of SERMs and their incidental biological activity (cholesterol accumulation), we hypothesized that this incidental biological activity induced by SERMs could be a plausible mechanism as to their inhibitory effects on Ebola infection. Herein, we demonstrated that the same dosages of SERMs which induced cholesterol accumulation also inhibited Ebola infection. SERMs reduced the cellular sphingosine and subsequently caused endolysosomal calcium accumulation, which in turn led to blocking the Ebola entry. Our study clarified the specific anti-Ebola mechanism of SERMs, even the cationic amphiphilic drugs (CADs), this mechanism led to the endolysosomal calcium as a critical target for development of anti-Ebola drugs.
has issue date	2017-01-24(xsd:dateTime)
bibo:doi	10.1038/srep41226
bibo:pmid	28117364
has license	cc-by
sha1sum (hex)	62641fdbeeff7b487788b42b59a3d1ca66bdb978
schema:url	https://doi.org/10.1038/srep41226
resource representing a document's title	Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium
has PubMed Central identifier	PMC5259750
has PubMed identifier	28117364
schema:publication	Sci Rep
resource representing a document's body	covid:62641fdbeeff7b487788b42b59a3d1ca66bdb978#body_text
is schema:about of	named entity 'effects' named entity 'dosages' named entity 'estrogen receptor' named entity 'WEST' named entity 'STUDY' named entity 'MECHANISM' named entity 'THEIR' named entity 'ACCUMULATION' named entity 'BLOCKING' named entity 'AMPHIPHILIC' named entity 'URGENCY' named entity 'SPECIFIC' named entity 'AVAILABLE' named entity 'CALCIUM' named entity 'CLARIFIED' named entity 'TURN' named entity 'THERAPEUTICS' named entity 'OPEN' named entity 'SELECTIVE' named entity 'CRISIS' named entity 'FOOD AND DRUG ADMINISTRATION' named entity 'CRITICAL' named entity 'ENTRY' named entity 'EBOLA' named entity 'CALCIUM' named entity 'INHIBITION' named entity 'ENTRY' named entity 'DISRUPTING' named entity 'SELECTIVE ESTROGEN RECEPTOR MODULATORS' named entity 'EFFECTS' named entity 'APPROVED' named entity 'CHOLESTEROL' named entity 'DEVELOPMENT' named entity 'INCIDENTAL' named entity 'OCCURRED' named entity 'AFRICA' named entity 'POSSESS' named entity 'OUR' named entity 'SERMS' named entity 'CELLULAR' named entity 'EBOLA' named entity 'TREATMENTS' named entity 'ITS' named entity 'INHIBITORY MECHANISMS' named entity 'TARGET' named entity 'SELECTIVE' named entity 'INHIBITED' named entity 'CLINICAL' named entity 'REDUCED' named entity 'COULD BE' named entity 'DRUGS' named entity 'CURRENTLY' named entity 'ACTIVITIES' named entity 'DOSAGES' named entity 'THESE' named entity 'STRUCTURES' named entity 'CAUSED' named entity 'INDUCED' named entity 'BIOLOGICAL ACTIVITY' named entity 'INCLUDING' named entity 'LED' named entity 'DEMONSTRATED' named entity 'SPHINGOSINE' named entity 'INHIBITORY' named entity 'FDA' named entity 'INFECTION' named entity 'ANALYZING' named entity 'SELECTIVE ESTROGEN RECEPTOR MODULATORS' covid:arg/62641fdbeeff7b487788b42b59a3d1ca66bdb978

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software